Online citations, reference lists, and bibliographies.
← Back to Search

A Multicenter Study Of Volumetric Computed Tomography For Staging Malignant Pleural Mesothelioma.

V. Rusch, R. Gill, A. Mitchell, D. Naidich, D. Rice, H. Pass, H. Kindler, M. D. de Perrot, J. Friedberg
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Standard imaging modalities are inaccurate in staging malignant pleural mesothelioma (MPM). Single-institution studies suggest that volumetric computed tomography (CT) is more accurate but labor intensive. We established a multicenter network to test interobserver variability, accuracy (relative to pathologic stage), and the prognostic significance of semiautomated volumetric CT. METHODS Six institutions electronically submitted to an established multicenter database clinical and pathologic data for patients with MPM who had operations. Institutional radiologists reviewed preoperative CT scans for quality and then submitted by electronic network (AG Mednet, www.agmednet.com) to the biostatistical center. Two reference radiologists blinded to clinical data performed semiautomated tumor volume calculations using Vitrea Enterprise 6.0 software (Vital Images, Minnetonka, MN) and then submitted readings to the biostatistical center. Study end points included feasibility of the network, interobserver variability for volumetric CT, correlation of tumor volume to pTN stages, and overall survival (OS). RESULTS Of 164 patients, the CT scans for 129 were analyzable and read by reference radiologists. Most tumors were less than 500 cm(3). A small bias was observed between readers because one provided consistently larger measurements than the other (mean difference, 47.9; p = .0027), but for 80%, the absolute difference was 200 cm(3) or less. Spearman correlation between readers was 0.822. Volume correlated with pTN stages and OS, best defined by three groups with average volumes of 91.2, 245.3, and 511.3 cm(3) associated with median OS of 37, 18, and 8 months, respectively. CONCLUSIONS For the first time, a multicenter network was established and initial correlations of tumor volume with pTN stages and OS are shown. A larger multicenter international study is planned to confirm the results and refine correlations.
This paper references
10.1118/1.3525836
Computerized segmentation and measurement of malignant pleural mesothelioma.
W. Sensakovic (2011)
10.1097/JTO.0b013e3181dd0ef1
Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans
F. Liu (2010)
10.1183/09031936.00146110
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
10.1016/j.ejrad.2009.02.002
Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
G. Ak (2010)
10.2214/AJR.11.7015
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
R. Gill (2012)
10.1378/CHEST.129.6.1570
Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.
F. Giesel (2006)
10.1016/S0022-5223(98)70274-0
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)
10.9738/CC66.1
Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma.
N. Mollberg (2012)
10.1148/RADIOL.2291020859
Effect of varying CT section width on volumetric measurement of lung tumors and application of compensatory equations.
H. Winer-Muram (2003)
10.1016/J.ACRA.2005.05.021
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.
S. Armato (2005)
10.1016/j.athoracsur.2008.03.016
A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
H. Pass (2008)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1118/1.1688211
Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.
S. Armato (2004)
10.1158/1078-0432.CCR-09-2313
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)
10.1016/j.jtho.2016.04.027
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study
R. Gill (2016)
10.1007/s00330-008-0918-9
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
C. Plathow (2008)



This paper is referenced by
10.1097/MCP.0000000000000389
Surgery as part of radical treatment for malignant pleural mesothelioma
D. Waller (2017)
10.1111/1759-7714.13456
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population‐based nationwide study
A. Trama (2020)
10.1259/bjr.20180631
Volumetric analysis at abdominal CT: oncologic and non-oncologic applications.
Virginia B. Planz (2019)
10.1007/978-3-319-52619-5_36-1
Radiation Therapy in Mesothelioma
J. Willmann (2019)
Zahlen und Fakten zum Pleuramesotheliom im 21. Jahrhundert: Epidemiologie, Diagnostik, Therapie // Numbers and facts regarding the malignant pleural mesothelioma in the 21st century: epidemiology, diagnostics, therapy
Watzka Sb (2019)
10.1016/j.jtcvs.2019.11.035
Preoperative prediction of unresectability in malignant pleural mesothelioma.
B. Burt (2019)
10.5761/atcs.oa.17-00192
Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.
T. Miyazaki (2018)
10.2967/jnumed.119.238733
18F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysis—The Central Role of Volume
J. Reynolds (2020)
10.1016/j.mayocp.2018.01.032
Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma
A. Mansfield (2018)
10.1007/978-3-319-96244-3_17
Understanding Clinical Trials in Malignant Mesothelioma
A. Mansfield (2019)
10.1158/1055-9965.EPI-20-0543
Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma
Ferdinando Cerciello (2020)
10.1016/j.jtcvs.2018.09.106
Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma
M. Hashimoto (2019)
10.1117/1.JMI.7.1.012705
Deep learning-based segmentation of malignant pleural mesothelioma tumor on computed tomography scans: application to scans demonstrating pleural effusion
E. Gudmundsson (2020)
10.3322/caac.21572
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
M. Carbone (2019)
10.1016/S1470-2045(17)30459-X
Radiotherapy for the treatment of malignant pleural mesothelioma.
M. Perrot (2017)
10.1016/j.jtho.2016.04.027
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study
R. Gill (2016)
10.1016/j.jtho.2018.02.021
State of the Art : Advances in Malignant Pleural Mesothelioma in 2017
Amanda J McCambridge (2018)
10.1093/annonc/mdy195
Pleural mesothelioma: is the surgeon still there?
I. Opitz (2018)
10.1016/J.CLLC.2019.06.019
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
C. Proto (2019)
10.1183/13993003.00319-2017
Malignant pleural mesothelioma: new treatments, new hopes?
A. Scherpereel (2017)
10.5858/arpa.2017-0245-RA
Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist.
A. Nicholson (2018)
10.1007/978-3-319-96244-3
Caring for Patients with Mesothelioma: Principles and Guidelines
M. Hesdorffer (2019)
10.1016/J.JTHO.2019.04.029
A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Taskforce
J. Friedberg (2019)
10.1183/13993003.00953-2019
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
10.1093/jnci/djx175
Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma
R. Gill (2018)
10.1016/j.cllc.2020.06.002
Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study.
Akash M Patel (2020)
10.1016/j.lungcan.2018.11.033
Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
S. Armato (2019)
10.1097/RCT.0000000000000727
Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?
J. Escalon (2018)
10.1016/j.jtcvs.2020.01.034
Commentary: Know your enemy-Understanding futility in the battle against malignant pleural mesothelioma.
Andrew E. Giles (2020)
10.21037/atm.2017.05.23
Volumetric assessment in malignant pleural mesothelioma.
D. Murphy (2017)
10.1016/j.lungcan.2017.09.015
Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma.
O. Abdel-Rahman (2017)
10.1016/j.lungcan.2018.01.001
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
Juuso Paajanen (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar